15 analysts have shared their evaluations of Exelixis EXEL during the recent three months, expressing a mix of bullish and bearish perspectives.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 6 | 6 | 3 | 0 | 0 |
| Last 30D | 1 | 1 | 0 | 0 | 0 |
| 1M Ago | 2 | 1 | 2 | 0 | 0 |
| 2M Ago | 0 | 0 | 0 | 0 | 0 |
| 3M Ago | 3 | 4 | 1 | 0 | 0 |
In the assessment of 12-month price targets, analysts unveil insights for Exelixis, presenting an average target of $37.13, a high estimate of $42.00, and a low estimate of $29.00. This current average reflects an increase of 15.06% from the previous average price target of $32.27.
Investigating Analyst Ratings: An Elaborate Study
A clear picture of Exelixis's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Asthika Goonewardene | Truist Securities | Raises | Buy | $42.00 | $38.00 |
| Silvan Tuerkcan | JMP Securities | Raises | Market Outperform | $41.00 | $34.00 |
| Joseph Catanzaro | Piper Sandler | Raises | Overweight | $37.00 | $36.00 |
| Robert Burns | HC Wainwright & Co. | Raises | Buy | $40.00 | $29.00 |
| Michael Schmidt | Guggenheim | Raises | Buy | $42.00 | $33.00 |
| Etzer Darout | BMO Capital | Raises | Market Perform | $40.00 | $36.00 |
| Jason Gerberry | B of A Securities | Raises | Neutral | $39.00 | $35.00 |
| Michael Schmidt | Guggenheim | Raises | Buy | $33.00 | $32.00 |
| Sudan Loganathan | Stephens & Co. | Raises | Equal-Weight | $29.00 | $23.00 |
| Joseph Catanzaro | Piper Sandler | Raises | Overweight | $36.00 | $33.00 |
| Gregory Renza | RBC Capital | Maintains | Outperform | $34.00 | $34.00 |
| Asthika Goonewardene | Truist Securities | Raises | Buy | $38.00 | $33.00 |
| Derek Archila | Wells Fargo | Raises | Overweight | $36.00 | $32.00 |
| Etzer Darout | BMO Capital | Raises | Outperform | $36.00 | $29.00 |
| Yaron Werber | TD Cowen | Raises | Buy | $34.00 | $27.00 |
Key Insights:
- Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Exelixis. This information provides a snapshot of how analysts perceive the current state of the company.
- Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Exelixis compared to the broader market.
- Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Exelixis's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
Stay up to date on Exelixis analyst ratings.
Discovering Exelixis: A Closer Look
Exelixis is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its lead molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
Understanding the Numbers: Exelixis's Finances
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Positive Revenue Trend: Examining Exelixis's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 14.33% as of 30 September, 2024, showcasing a substantial increase in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Exelixis's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 21.87%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Exelixis's ROE stands out, surpassing industry averages. With an impressive ROE of 5.37%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Exelixis's ROA excels beyond industry benchmarks, reaching 4.12%. This signifies efficient management of assets and strong financial health.
Debt Management: Exelixis's debt-to-equity ratio is below the industry average. With a ratio of 0.09, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
Analyst Ratings: What Are They?
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. Click here to stay ahead of the market.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
